A Study of SHP655 (rADAMTS13) in Sickle Cell Disease
Public ClinicalTrials.gov record NCT03997760. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Randomized, Double-blind, Placebo-controlled, Multicenter, Ascending Dose, Safety and PK/PD Study of SHP655 (rADAMTS13) in Sickle Cell Disease at Baseline Health
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
TAK-755 (previously known as SHP655) is a medicine used to treat sickle cell disease (SCD). The main aim of the study is to measure the safety and tolerability of TAK-755 in SCD participants. Study participants will receive TAK-755 or placebo on Day 1. Their SCD will be treated by their doctor according to their doctor's usual clinical practice. During the study, participants will be asked to follow-up on 13 days following SHP655 or placebo administration for safety assessment. Maximum duration of participation is expected to be about 2 months.
Study identification
- NCT ID
- NCT03997760
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 19 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 21, 2019 (Actual)
- Primary completion
- Oct 26, 2022 (Actual)
- Completion
- Oct 26, 2022 (Actual)
- Last update posted
- Apr 23, 2024
2019 – 2022
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | — |
| Arkansas Children's Hospital | Little Rock | Arkansas | 77202 | — |
| University of Colorado Sickle Cell Treatment and Research Center | Aurora | Colorado | 80045 | — |
| Sickle Cell Center | Denver | Colorado | 80262 | — |
| University of Illinois | Chicago | Illinois | 60612-4325 | — |
| Ochsner Health System | New Orleans | Louisiana | 70121 | — |
| Johns Hopkins University School Of Medicine | Baltimore | Maryland | 21218 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Duke University Medical Center | Durham | North Carolina | 27705 | — |
| East Carolina University | Greenville | North Carolina | 27858 | — |
| Ohio State University Medical Center | Columbus | Ohio | 43210 | — |
| Medical University of South Carolina (MUSC) | Charleston | South Carolina | 29425 | — |
| University of Tennessee -- Memphis | Memphis | Tennessee | 38163-2116 | — |
| VCU Health - Research Parent | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03997760, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 23, 2024 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03997760 live on ClinicalTrials.gov.